Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3547-3554

  Chen, Liyu ^a,b   Ao, Zhujun ^a   Jayappa, Kallesh Danappa ^a   Kobinger, Gary ^c   Liu, Shuiping ^b   Wu, Guojun ^b   Wainberg, Mark A ^d   Yao, Xiaojian ^a  

^a Faculty of Medicine   (Canada)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AH 0109; BENZAMIDE DERIVATIVE; COMPLEMENTARY DNA; LAMIVUDINE; NEVIRAPINE; RALTEGRAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE CONTROL; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS STRAIN;

ACTIVE TRANSPORT, CELL NUCLEUS; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MORPHINANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTION; VIRUS REPLICATION; ZIDOVUDINE;

EID: 84880258691     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00100-13     Document Type: Article

References (34)

1. Demberg T, Robert-Guroff M. 2012. Controlling the HIV/AIDS epidemic: current status and global challenges. Front. Immunol. 3:250.
2. Richman DD. 1993. HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 33:149.
3. von Wyl V, Yerly S, Boni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Gunthard HF. 2011. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin. Infect. Dis. 54:131-140.
4. Prasad VR, Goff SP. 1990. Structure-function studies of HIV reverse transcriptase. Ann. N. Y. Acad. Sci. 616:11-21.
5. Chiu TK, Davies DR. 2004. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4:965-977.
6. Ao Z, Fowke KR, Cohen EA, Yao X. 2005. Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import. Retrovirology 2:62.
7. Gallay P, Hope T, Chin D, Trono D. 1997. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/ karyopherin pathway. Proc. Natl. Acad. Sci. U. S. A. 94:9825-9830.
8. Ao Z, Danappa Jayappa K, Wang B, Zheng Y, Kung S, Rassart E, Depping R, Kohler M, Cohen EA, Yao X. 2010. Importin 3 interacts with HIV-1 integrase and contributes to HIV-1 nuclear import and replication. J. Virol. 84:8650-8663.
9. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, Engelborghs Y. 2003. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278:33528-33539.
10. Adamson CS, Freed EO. 2010. Novel approaches to inhibiting HIV-1 replication. Antivir. Res. 85:119-141.
11. Temesgen Z, Warnke D, Kasten MJ. 2006. Current status of antiretroviral therapy. Expert Opin. Pharmacother. 7:1541-1554.
12. Clercq ED. 2009. Anti-HIV drugs:25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33:307-320.
13. Le Grice SF. 2012. Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise. J. Biol. Chem. 287: 40850-40857.
14. Hazuda DJ. 2012. HIV integrase as a target for antiretroviral therapy. Curr. Opin. HIV AIDS 7:383-389.
15. Didigu CA, Doms RW. 2012. Novel approaches to inhibit HIV entry. Viruses 4:309-324.
16. Ao Z, Wang X, Bello AJ, Danappa Jayappa K, Yu Z, Fowke K, He X, Chen X, Li J, Kobinger GP, Yao X. 2011. Characterization of anti-HIV activity mediated by R88-Apobec3G mutant fusion proteins in CD4 T cells, PBMCs, and macrophages. Hum. Gene Ther. 22:1225-1237.
17. Ao Z, Yu Z, Wang L, Zheng Y, Yao X. 2008. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One 3:e1995. doi:10.1371/journal.pone .0001995.
18. Zheng Y, Ao Z, Wang B, Jayappa KD, Yao X. 2011. Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication. J. Biol. Chem. 286:17722-17735.
19. Bar-Magen T, Sloan R, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84:9210-9216.
20. Soudeyns H, Yao XI, Gao Q, Belleau B, Kraus JL, Nguyen-Ba N, Spira B, Wainberg MA. 1991. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2=-deoxy-3=-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35: 1386-1390.
21. Jayappa KD, Ao Z, Yang M, Wang J, Yao X. 2011. Identification of critical motifs in HIV-1 integrase required for importin 3 interaction and its involvement in viral cDNA nuclear import. J. Mol. Biol. 410:847-862.
22. Han H, He W, Wang W, Gao B. 2011. Inhibitory effect of aqueous dandelion extract on HIV-1 replication and reverse transcriptase activity. BMC Complement Altern. Med. 11:112. doi:10.1186/1472-6882-11-112.
23. Hu Z, Kuritzkes DR. 2011. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1 J. Virol. 85:11309-11314.
24. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A. 90:8033-8037.
25. Yao X-J, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA. 1995. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69:7032-7044.
26. Schiller DS, Youssef-Bessler M. 2009. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther. 31:692-704.
27. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
28. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. U. S. A. 88:11241-11245.
29. Maga G, Radi M, Gerard MA, Botta M, Ennifar E. 2010. HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate. Viruses 2:880-899.
30. Jayappa KD, Ao Z, Yao X. 2012. The HIV-1 passage from cytoplasm to nucleus: the process involving a complex exchange between the components of HIV-1 and cellular machinery to access nucleus and successful integration. Int. J. Biochem. Mol. Biol. 3:70-85.
31. Popov S, Dubrovsky L, Lee MA, Pennathur S, Haffar O, LAYa Tonge P, Ulrich P, Rexach M, Blobel G, Cerami A, Bukrinsky M. 1996. Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 93:11859-11864.
32. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kucherer C, Struck D, Schmit JC, Asjo B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA. 2009. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 200:1503-1508.
33. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, Mahle KC, Heneine W, Johnson JA, Hall HI. 2010. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24:1203-1212.
34. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2008. Update of the drug resistance mutations in HIV-1: Spring 2008. Top. HIV Med. 16:62-68.